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Abstract
We examined the feasibility of triplet chemotherapy using cisplatin, docetaxel, and irinote-
can for patients with recurrent or refractory non-small cell lung cancer (NSCLC), retrospectively.
Twenty-five patients (21 men and 4 women) with NSCLC and good performance status who were
<70 years old were analyzed. The median age was 58 years. Most patients had performance status
1 (16/25), stage IV disease (18/25) and adenocarcinoma-histology (16/25). Cisplatin and docetaxel
were given on day 1 and irinotecan on day 2;the cycle was repeated every 3 weeks. The objective
response rate was 39.1% (95% confidence interval:18.7-59.5%). The median survival time and ac-
tual 2-, 3-, and 5-year survival rates were 14.3 months, 32%, 20%, and 8%, respectively. Of note,
only 6 patients were treated with gefitinib at the recurrence after triplet chemotherapy;of these, 4
(67%) achieved a partial response, which might result in favorable survival. Grade 3/4 toxicities
consisted of neutropenia (100%), neutropenic fever (56%), nausea/vomiting (40%), and diarrhea
(16%);no cases of treatment-related death occurred. Triplet chemotherapy showed impressive sur-
vival data in our clinical trial, but proved too toxic for use in treating patients with NSCLC in the
clinical practice.
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We examined the feasibility of triplet chemotherapy using cisplatin,  docetaxel,  and irinotecan for 
patients with recurrent or refractory non-small cell lung cancer (NSCLC),  retrospectively.  Twenty-
ﬁve patients (21 men and 4 women) with NSCLC and good performance status who were ｦ70 years old 
were analyzed.  The median age was 58 years.  Most patients had performance status 1 (16/25),  stage 
IV disease (18/25) and adenocarcinoma-histology (16/25).  Cisplatin and docetaxel were given on day 1 
and irinotecan on day 2; the cycle was repeated every 3 weeks.  The objective response rate was 
39.1ｵ (95ｵ conﬁdence interval: 18.7-59.5ｵ).  The median survival time and actual 2-,  3-,  and 5-year 
survival rates were 14.3 months,  32ｵ,  20ｵ,  and 8ｵ,  respectively.  Of note,  only 6 patients were 
treated with geﬁtinib at the recurrence after triplet chemotherapy; of these,  4 (67ｵ) achieved a par-
tial response,  which might result in favorable survival.  Grade 3/4 toxicities consisted of neutropenia 
(100ｵ),  neutropenic fever (56ｵ),  nausea/vomiting (40ｵ),  and diarrhea (16ｵ); no cases of treatment-
related death occurred.  Triplet chemotherapy showed impressive survival data in our clinical trial,  
but proved too toxic for use in treating patients with NSCLC in the clinical practice.
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ung cancer is a leading cause of cancer death 
worldwide including Japan.  Platinum-based 
combination chemotherapy is the standard care for 
patients with advanced non-small cell lung cancer 
(NSCLC) [1].  At present,  docetaxel,  pemetrexed,  
erlotinib,  and geﬁtinib are used as second-line treat-
ments for recurrent or refractory advanced NSCLC 
[2-5].
　 A phase I/II clinical trial of combination chemo-
therapy with cisplatin,  docetaxel,  and irinotecan for 
untreated patients with advanced NSCLC demon-
strated promising results in objective response rate 
and in survival [6].  Three drugs were selected to 
obtain the best response based on the interactions 
between 2 drugs [7],  two-drug schedule dependency 
[8] and the sensitivity spectrum of each drug to lung 
cancer cell lines [9] in ex vivo experiments [6].  
Although a phase III trial (OLCSG 0403) is ongoing 
to conﬁrm the superiority of triplet over doublet che-
motherapy,  the results of the phase I/II trial encour-
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aged us to expand triplet chemotherapy to patients 
with recurrent or refractory NSCLC who were 
excluded from the original phase I/II trial [6].
　 We describe here the results of a particular triplet 
chemotherapy for relatively young NSCLC patients 
with good performance status (PS) and adequate organ 
function who were treated previously.
Patients and Methods
　 Patients. Twenty-ﬁve patients aged ｦ70 years 
with Eastern Clinical Oncology Group (ECOG) PS of 
0 to 1 and who had histologically or cytologically 
conﬁrmed NSCLC were treated with triplet chemo-
therapy.  All patients had received prior therapy,  such 
as surgery and/or thoracic curative and palliative 
radiotherapy,  or systemic chemotherapy,  and did not 
require measurable lesions.  Prior treatments had to 
have been completed at least 4 weeks prior to triplet 
chemotherapy.  Other inclusion and exclusion criteria 
were the same as those for the phase II trial previ-
ously reported [6].  Brieﬂy,  patients had to have 
adequate functioning of the bone marrow [white blood 
cell (WBC) count of 4,000 to 12,000/µl,  and platelets 
ｧ100,000/µl],  kidneys [serum creatinine level 
＜1.5mg/dl,  24-h creatinine clearance (Ccr) ｧ60ml/
min],  and liver (total bilirubin level ｦ1.5mg/dl,  
alanine transaminase and asparagine transaminase 
levels no more than twice the upper limit of normal 
values).  Patients were excluded if they had a second 
primary tumor other than basal cell carcinoma of the 
skin or carcinoma in situ of the cervix,  severe cardio-
pulmonary insuﬃciency,  severe angina pectoris or 
myocardial infarction,  active infection,  uncontrolled 
diabetes mellitus,  or a life expectancy of less than 3 
months.  Written informed consent was obtained prior 
to treatment.
　 Baseline evaluation. Tumors were staged on 
the basis of a physical examination,  routine chest 
radiograph,  bone scintigraphy,  computed tomography 
of the chest and abdomen,  enhanced magnetic reso-
nance imaging of the brain,  and ﬁber optic bronchos-
copy.  Stages were assessed according to the Union 
International Contra le Cancer TNM classiﬁcation for 
lung cancer staging [10].
　 Treatment: triplet regimen. We adminis-
tered cisplatin (60mg/m2) and docetaxel (60mg/m2) on 
day 1,  and irinotecan (50mg/m2) on day 2.  Because 
patients analyzed had undergone prior therapies,  the 
dose of irinotecan was held at 50mg/m2.  The schedule 
used was the same as previously described [6] except 
for the irinotecan dose.  Brieﬂy,  on day 1,  docetaxel 
was given as a 1-h infusion,  and cisplatin was adminis-
tered subsequently as a 1-h infusion.  On day 2,  irino-
tecan was given as a 1-h infusion.  If patients experi-
enced grade 4 neutropenia or febrile neutropenia in the 
ﬁrst cycle,  they received leno grastim or ﬁlgrastim 
prophylactically in the subsequent cycles.  The triplet 
regimen was repeated every 3 weeks when patients 
had recovered from any drug-related toxicities associ-
ated with the previous cycle other than grade 1 neu-
tropenia.  The cisplatin dose was reduced to 30mg/m2 
if a patientʼs Ccr level was 30-60ml/min.  Cisplatin 
was discontinued if the Ccr level fell below 30ml/min.  
If patients experienced any grade 3 toxicities other 
than renal impairment,  chemotherapy was repeated 
with a 10mg/m2 reduction of irinotecan.  
Chemotherapy was continued until the disease pro-
gressed or until unacceptable toxicity developed.  Each 
physician decided the treatments following triplet 
chemotherapy.  All patients who survived have 
received geﬁtinib since September,  2002.
　 Follow-up evaluation. Tumor response was 
assessed at every chemotherapy cycle using the WHO 
criteria [7].  Toxicity was assessed and graded using 
the National Cancer Institute Common Toxicity 
Criteria (NCI-CTC,  version 2.0,  revised in 1998).  A 
complete blood count (CBC) including a diﬀerential 
WBC count and blood chemistry was repeated at least 
once a week; if the absolute neutrophil count 
decreased to ｦ500/µl or if the leukocyte count was 
ｦ1,000/µl,  the CBC was repeated every day until 
recovery.
　 Statistical considerations. The overall sur-
vival time was deﬁned as the period from the beginning 
of treatment until death or the last follow-up evalua-
tion,  and the time to progression (TTP) was deﬁned 
as the period from the beginning of treatment until 
progressive disease (PD) or until death from causes 
other than NSCLC.  Survival curves were calculated 
using the Kaplan-Meier method.
Results
　 Patient characteristics. Between October,  
1998 and July,  2001,  25 patients with NSCLC who 
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met our criteria were consecutively treated at 
Okayama University Hospital with triplet chemother-
apy.  The characteristics of the patients are listed in 
Table 1.  The group consisted of 21 men and 4 women,  
with a median age of 58 years (range,  40-67 years).  
Sixteen patients (64ｵ) had adenocarcinoma,  7 (28ｵ) 
had squamous cell carcinoma,  and 1 patient each had 
large cell and signet ring cell carcinoma (4ｵ).  All 
patients had an ECOG PS of 0 to 1 and had under-
gone prior therapy: 13 patients had palliative radio-
therapy for metastatic lesions of the brain or the 
bone,  6 patients had recurrent disease after surgery,  
and 6 patients were refractory to ﬁrst-line platinum-
based systemic chemotherapies consisting of cisplatin,  
mitomycin-C,  and vindesine,  or of cisplatin and 5-ﬂu-
orouracil.  Following triplet chemotherapy,  12 
patients received no additional treatments,  6 received 
palliative radiotherapy,  6 geﬁtinib,  2 vinorelbine,  2 
gemcitabine＋vinorelbine,  1 gemcitabine,  1 carbopl-
atin＋gemcitabine,  and 1 carboplatin＋paclitaxel.
　 Response. Among the 25 patients,  2 who had 
no measurable lesions had been treated with systemic 
chemotherapy.  One had malignant pleural eﬀusion,  
and another could not be evaluated for tumors because 
of in-ﬁeld recurrence after radiotherapy.  Responses 
of the 23 remaining patients were as follows: 1 
(4.3ｵ) CR,  8 (34.8ｵ) partial response (PR),  10 no 
change (NC) (43.5ｵ),  and 4 (17.4ｵ) PD.  The overall 
response rate was 39.1ｵ (95ｵ CI: 18.7-59.5ｵ).  
Responses of the 19 chemotherapy-naïve patients were 
as follows: 1 (5.3ｵ) CR,  6 (31.6ｵ) PR,  8 (42.1ｵ) 
NC,  and 4 (21.1ｵ) PD,  for an overall response rate 
of 36.8ｵ (95ｵ CI: 14.6-59.1ｵ).  Two (50ｵ) of 4 
evaluable patients previously treated with platinum-
based systemic chemotherapy achieved a PR.
　 Only 6 patients (24ｵ) had been treated after dis-
ease progression with geﬁtinib,  which was not 
approved in Japan until August,  2002.  Of the 6 
patients,  4 (66ｵ) achieved a PR,  including 1 patient 
whose tumor genome contained a 752-759 deletion 
mutation in exon 19 of the EGFR tyrosine kinase 
domain,  as detected in a surgical specimen.
　 Survival. Fig.  1 shows the overall survival 
curve for the 25 patients.  At a median follow-up time 
of 96.1 months (95ｵ CI: 86.2-106.1 months),  1 
patient (4ｵ) was alive with lung cancer.  The overall 
survival rates at 1,  2,  3,  and 5 years were 48,  32,  
20,  and 8ｵ,  respectively.  The median survival time 
(MST) and the median TTP were 14.3 months (95ｵ 
CI: 8.8-19.8 months) and 5.4 months (95ｵ CI: 4.6-
6.2 months),  respectively.  Six patients (24ｵ) were 
treated with geﬁtinib after triplet chemotherapy.  
Surprisingly,  the response rate and disease control 
rate [CR＋PR＋NC] for geﬁtinib treatment were 67 
and 100ｵ,  respectively.  The response duration of 
geﬁtinib treatment ranged from 8 to 28 months.  
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Table 1　 Patient characteristics
No. of patients analyzed 25　　
No. of patients with measurable lesions 23　　
Median age,  years (range) 58 (40-67)
Gender,  male/female 21/4 　
Performance status 0 9 　　
1 16　　
Histology
　　Adenocarcinoma 16　　
　　Squamous cell carcinoma 7 　　
　　Large cell carcinoma 1 　　
　　Signet ring cell carcinoma 1 　　
Stage when treated with triplet chemotherapy
　　　　IIIB 4 　　
　　　　IV 18　　
　　　　First relapse after surgical resection  
　　　　with a single recurrence site
3 　　
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Fig. 1　 Overall survival from the beginning of triplet chemother-
apy for 25 previously treated patients with NSCLC.  Open circles 
represent 6 patients treated with geﬁtinib following triplet chemo-
therapy.  The tic indicates a censored case.
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Furthermore,  the survival times of the 6 patients 
treated with triplet chemotherapy followed by geﬁtinib 
were 83.3,  81.4 (survival),  40.4,  39.0,  35.9 and 29.0 
months,  as indicated by open circles in Fig.  1.
　 Toxicity. The hematological and non-hemato-
logical toxicities observed in all 25 patients during 
treatment are listed in Tables 2 and 3,  respectively.  
The most common toxicities were leukopenia and 
neutropenia.  Both grade 3/4 leukopenia and neutro-
penia were observed in the 25 patients (100ｵ).  The 
median neutrophil count nadir was 125/µl (range 
11-486/µl).  The median days to nadir,  the median 
duration of grade 4 neutropenia,  and the median 
length of recombinant human granulocyte-colony stimu-
lating factor (rhG-CSF) administration were 9 days 
(range 7-13 days),  3 days (range 5-7 days),  and 6 
days (range 4-12 days),  respectively.  rhG-CSF was 
administered in 70 (98.6ｵ) of 71 cycles.  Grade 3/4 
thrombocytopenia and anemia occurred in 1 (4ｵ) and 
4 (16ｵ) patients,  respectively.  Grade 3/4 nausea/
vomiting and diarrhea occurred in 10 (40ｵ) and 4 
(16ｵ) patients,  respectively.  Fourteen patients 
(56ｵ) developed febrile neutropenia and recovered 
uneventfully following treatment with intravenous 
broad-spectrum antibiotics and rhG-CSF support.  No 
treatment-related deaths occurred.
　 Table 4 summarizes the actual dose rate in the 
regimens,  individual drugs used,  and the number of 
cycles.  Those patients receiving a third or fourth 
cycle of triplet chemotherapy received over 90ｵ of 
the full dose of each drug.
Discussion
　 The triplet chemotherapy of cisplatin,  docetaxel,  
and irinotecan demonstrated an MST of 14.3 months 
with severe,  but manageable toxicities and a favorable 
response rate of 39.1ｵ among refractory or previ-
ously treated patients with NSCLC.  Survival was 
markedly higher than expected,  because the MST in 
this analysis corresponded to that of 11 to 14 months 
in untreated advanced NSCLC patients [11].
　 Treatments following the triplet regimen may have 
had an impact on long-term survival,  although 48ｵ of 
patients did not receive any follow-up treatments,  
24ｵ received palliative radiotherapy,  and only 24ｵ 
received further single-drug or doublet chemotherapy.  
Note that the response rate and response duration of 
the 6 patients treated with geﬁtinib at the recurrence 
after triplet chemotherapy are very high.  Moreover,  
the survival times of these six patients ranged from 29 
to 83 months.  Although the phenomena might be by 
chance because of a small sample size,  docetaxel was 
reported to be eﬀective for patients with NSCLC 
harboring epidermal growth factor receptor (EGFR) 
mutations [5].  In addition,  the 5-year survival rate of 
patients with advanced/recurrent NSCLC harboring 
activating EGFR mutations was 50ｵ or more [12].  
Patients responding to triplet chemotherapy between 
1998 and 2001 could live long enough to have a chance 
to receive geﬁtinib,  as geﬁtinib was approved in 
August,  2002 in Japan.  We presume that long survi-
vors selected by triplet chemotherapy including doc-
etaxel might possess activating EGFR mutations,  
although EGFR status was checked in only 1 patient 
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Table 2　 Hematologic toxicity
Grade
0 1 2 3 4 3 and 4 (%)
Leukocytopenia  0 0 0 11 14 25 (100)
Neutropenia  0 0 0  1 24 25 (100)
Anemia  7 8 6  4  0 4 ( 16)
Thrombocytopenia 21 2 1  0  1 1 (　4)
Table 3　 Non-hematologic toxicity
Grade
0 1 2 3 4 3 and 4 (%)
Nausea/vomiting 0  7 10  8 0 8 (32)
Diarrhea 13  6  4  2 0 2 ( 8)
Neutropenic fever 11 ― ― 14 0 14 (56)
Liver 16  4  5  0 0 0
Renal 22  3  0  0 0 0
Peripheral neuropathy 25  0  0  0 0 0
Alopecia 12 11  2 ― ― 0
Other 25  0  2  0 0 0
Table 4　 Compliance of chemotherapy and actual doses deliv-
ered of cisplatin,  docetaxel,  and irinotecan
No. of
cycles
No. of
patients
No. of patients 
treated without dose 
reduction (%)
Actual dose (mg/m2) delivered
Cisplatin Docetaxel Irinotecan
1 25 25 (100) 60 60 50
2 22 17 ( 77) 59 60 48
3 13 9 (69.2) 58 60 47
4  9 6 ( 67) 57 60 47
5  2 1 ( 50) 60 60 45
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retrospectively.  We are currently conducting a pro-
spective trial of this triplet chemotherapy followed by 
geﬁtinib on patients who have advanced/metastatic 
NSCLC with activating EGFR mutations (OLCSG 
0704) according to our clinical experiences based on 
this and previous trials [6,  12].
　 Nineteen of 25 patients analyzed were chemother-
apy-naïve patients who relapsed after surgical resec-
tion,  or who underwent palliative radiotherapy for 
metastatic lesions to the brain or bone.  Patients who 
underwent surgery and had a single brain metastasis 
or a single bone metastasis formed a subgroup of 
patients with advanced NSCLC.  These patients were 
excluded from the common clinical trials against 
advanced /metastatic NSCLC only because they had a 
pretreatment other than chemotherapy.  This analysis 
shows the possibility of intensive chemotherapy in a 
speciﬁc population in a strict clinical trial setting.
　 Toxicities were a main concern in this triplet che-
motherapy,  and were similar to those seen in the 
previous phase II trial [6].  Since more than 50ｵ of 
patients experienced neutropenic fever,  this triplet 
chemotherapy is unlikely to be used in clinical prac-
tice.  Triplet chemotherapy,  however,  might be justi-
ﬁed with the support of prophylactic G-CSF in the 
setting of an aggressive clinical trial to pursue a CR,  
such as an OLCSG 0704 trial.
　 In conclusion,  toxicities were too great for clinical 
practice,  but response and survival with triplet che-
motherapy were favorable for previously treated 
patients with NSCLC.  The survival of responders to 
triplet chemotherapy who also received geﬁtinib was 
notable.  These ﬁndings should be conﬁrmed by our 
ongoing prospective trial.
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